Supply chain deadlock under a double squeeze: the deeper logic behind the implementation of U.S. pharmaceutical tariffs and the divergence in ocean freight rates

The global supply chain is entering an exceptionally challenging moment in history. Today (July 31), the United States’ Section 232 tariffs on certain patented drugs and their active ingredients officially take effect, with rates as high as 100%. At the same time, the duty-free grace period for generic medicines also ends today, meaning that from tomorrow, a large number of import-dependent healthcare products will face a devastating surge in costs. However, the policy blow is only the tip of the iceberg: importers and exporters must also contend with extreme freight volatility in an ocean shipping market split between “ice and fire.” While spot rates on trans-Pacific routes have recently fallen by about 20%, rates on European routes remain elevated at over US$6,000 per 20-foot equivalent unit (TEU). This double squeeze—“a sharp rise in policy-driven costs” and “uncontrollable transport costs”—is pushing global trade into an unprecedented predicament.

Behind this dual dilemma is a fierce collision between geopolitical maneuvering and the macroeconomic cycle. The implementation of the U.S. Section 232 pharmaceutical tariffs is, in essence, intended to force medical supply chains to reshore and reduce reliance on external manufacturing. This policy not only directly dismantles the existing cost structure of pharmaceutical procurement, but also compels multinational drug companies to reorganize their global production and distribution networks within an extremely short timeframe. Meanwhile, the divergence in ocean freight rates reflects the fragility of the global logistics network. The pullback in trans-Pacific rates is because U.S. retailers, seeking to avoid potential tariff risks, have already front-loaded and effectively pulled forward import demand for the second half of the year; the persistently high rates on European routes, by contrast, are due to the Red Sea crisis forcing vessels to detour around the Cape of Good Hope, severely consuming global effective capacity. When steep tariffs meet an unstable ocean shipping network, importers’ and exporters’ profit margins are being relentlessly squeezed.

This extreme market environment imposes exceptionally stringent requirements on logistics and supply chain management, especially for high-value, temperature-sensitive pharmaceutical products. The traditional “Just-In-Time” model has become powerless in the face of 100% tariffs and sailing schedules that can be delayed at any time. To cope with the cash-flow pressure brought by tariffs, many companies may choose to reduce shipment size per import, which undoubtedly increases the number of logistics batches and management costs. Even more challenging, if companies choose ocean freight to save transport costs, congestion and detours on European routes can easily extend transit times for cold-chain pharmaceuticals, increasing the risk of spoilage; but if they shift entirely to air freight, with air capacity also tight at present, transport costs will surge geometrically, further eroding profits already weakened by tariffs.

In the face of this supply chain storm, importers and exporters must fundamentally rebuild their logistics strategies. First, companies should establish a data-driven dynamic cost accounting model that comprehensively evaluates tariff changes, spot-rate volatility, and potential delay risks, so as to find the optimal balance between ocean and air freight, and between the spot market and long-term contracts. Second, diversifying sourcing and transport routes is the only way to spread risk. Companies should actively explore alternative production bases not affected by the new tariffs, and pair them with multimodal solutions such as sea-air transport to ensure supply chain continuity. Finally, strengthening end-to-end visibility management for cold-chain logistics is critical. With sailing schedules highly unstable, real-time monitoring of cargo temperature and location, together with robust contingency plans, is the last line of defense to safeguard high-value goods.

Under the double squeeze of policy and market forces, logistics is no longer merely a simple operation of moving goods from Point A to Point B, but a strategic decision that can determine a company’s survival. Faced with steep tariffs and sharply fluctuating freight rates, companies need more than transport tools—they need professional advisors with deep industry insight. Only by leveraging precise data analysis and extensive hands-on experience to tailor the most optimized transport solution for every shipment can they move forward steadily through the turbulence.

Handle logistics troubles.
WhatsApp: +852 9876 5432
www.hlt.hk